High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nae Yun Heo | - |
dc.contributor.author | 임영석 | - |
dc.contributor.author | 이한주 | - |
dc.contributor.author | 이영상 | - |
dc.contributor.author | 김강모 | - |
dc.contributor.author | 변관수 | - |
dc.contributor.author | 한광협 | - |
dc.contributor.author | 이관식 | - |
dc.contributor.author | 백승운 | - |
dc.contributor.author | 윤승규 | - |
dc.contributor.author | 서동진 | - |
dc.date.accessioned | 2021-09-06T09:13:32Z | - |
dc.date.available | 2021-09-06T09:13:32Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/105693 | - |
dc.description.abstract | Background/Aims: Identifying the impact of a patient’s ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study. Methods: The clinical data of 272 treatment-naïve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy. Results: For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2,the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings. Conclusions: Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter. (Clin Mol Hepatol 2013;19:60-69) | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | 대한간학회 | - |
dc.title | High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice | - |
dc.title.alternative | High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 변관수 | - |
dc.identifier.doi | 10.3350/cmh.2013.19.1.60 | - |
dc.identifier.scopusid | 2-s2.0-84886873333 | - |
dc.identifier.bibliographicCitation | Clinical and Molecular Hepatology, v.19, no.1, pp.60 - 69 | - |
dc.relation.isPartOf | Clinical and Molecular Hepatology | - |
dc.citation.title | Clinical and Molecular Hepatology | - |
dc.citation.volume | 19 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 60 | - |
dc.citation.endPage | 69 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001752027 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Medication adherence | - |
dc.subject.keywordAuthor | Hepatitis C | - |
dc.subject.keywordAuthor | Peginterferon alfa-2a | - |
dc.subject.keywordAuthor | Ribavirin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.